AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting

AstraZeneca plc AZN said that Enhertu prolonged survival and slowed the progression of metastatic breast cancer with low levels of a protein known as HER2.

  • Data from the pivotal DESTINY-Breast04 Phase 3 trial showed Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and overall survival (OS) in patients versus physician's choice of chemotherapy.
  • The improvement was "clinically meaningful" when compared with standard chemotherapy, it said, adding that detailed results of the late-stage trial would be presented at an as-yet-undisclosed medical conference.
  • Related: AstraZeneca-Daiichi Sankyo Share Detailed Enhertu Data In Gastric Cancer.
  • Enhertu is a HER2-directed antibody-drug conjugate (ADC) jointly developed by AstraZeneca and Daiichi Sankyo DSNKY.
  • The trial met the key secondary endpoint of PFS in patients with HER2-low metastatic breast cancer regardless of HR status.
  • The safety profile of Enhertu was consistent with previous clinical trials, with no new safety concerns identified. 
  • Overall interstitial lung disease (ILD) rates were consistent with that observed in late-line HER2-positive breast cancer trials of Enhertu, with a lower rate of Grade 5 ILD observed.
  • Price Action: AZN shares are up 3.49% at $61.95 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralbreast cancerBriefsPhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!